Amerikanische Gesellschaft für Hirudotherapie

Anticoagulation in pregnancy.

Review published in Cardiology clinics (2012)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewKlinische StudienArzneimittelentwicklungGoland et al. · Cardiology clinics, 2012

Abstract

Pregnancy-associated thrombosis is an important cause of morbidity and mortality during pregnancy. Anticoagulation therapy is an important component of the management of thrombotic complications in pregnancy but may result in fetal and maternal complications. Although evidence-based recommendations are available for the prevention and treatment of venous thromboembolism, the management of pregnant women with mechanical valves still presents a challenge, because there are no controlled clinical trials to provide guidelines for optimal antithrombotic therapy. This review presents information on anticoagulation therapy during pregnancy for thromboembolic prophylaxis in women with various cardiovascular disorders, focusing on patients with mechanical heart valves.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsAtrial FibrillationBlood Coagulation DisordersCardiomyopathiesFemaleHeart Valve DiseasesHeart Valve ProsthesisHumansPractice Guidelines as TopicPregnancyPregnancy Complications, CardiovascularPregnancy Complications, Hematologic

Zusammenfassung

Pregnancy-associated thrombosis is an important cause of morbidity and mortality during pregnancy. Anticoagulation therapy is an important component of the management of thrombotic complications in pregnancy but may result in fetal and maternal complications.

Warum dies für die Hirudotherapie relevant ist

This review addressed anticoagulation therapy during pregnancy, focusing on thromboembolic prophylaxis in women with mechanical heart valves and noting the absence of controlled clinical trials to guide optimal therapy in this population. The leech relevance is negligible — the abstract discusses conventional anticoagulants with no mention of leeches, hirudin, or leech-derived therapeutics. Caveat: no leech or hirudotherapy content; this article is only indirectly relevant to ASH's domain.

Zitation

Anticoagulation in pregnancy.

Goland et al. · Cardiology clinics, 2012

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.